Telmisartan and Amlodipine
- Generic Name
- Telmisartan and Amlodipine
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗原发性高血压。替代治疗：接受替米沙坦片和氨氯地平片联合治疗的患者可以改为接受相同成份剂量的本品治疗。添加治疗：本品适用于5mg氨氯地平单药治疗无效有效控制血压的患者。
- Associated Conditions
- -
- Associated Therapies
- -
Telmisartan 80mg Non-responder Trial
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 174
- Registration Number
- NCT01222520
- Locations
- 🇯🇵
1235.36.04 Boehringer Ingelheim Investigational Site, Hiroshima, Hiroshima, Japan
🇯🇵1235.36.02 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan
🇯🇵1235.36.01 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 858
- Registration Number
- NCT00860262
- Locations
- 🇧🇬
1235.20.008 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
🇭🇺1235.20.152 Boehringer Ingelheim Investigational Site, Budapest, Hungary
🇷🇴1235.20.254 Boehringer Ingelheim Investigational Site, Iasi, Romania
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath